help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lehmann, M.
Right arrow Articles by Pommier, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lehmann, M.
Right arrow Articles by Pommier, G.
Endocrinology Vol. 139, No. 9 3763-3771
Copyright © 1998 by The Endocrine Society


ARTICLES

Deficient Processing and Activity of Type I Insulin-Like Growth Factor Receptor in the Furin-Deficient LoVo-C5 Cells1

Maxime Lehmann, Frédéric André, Catherine Bellan, Maryse Remacle-Bonnet, Francoise Garrouste, Fabrice Parat, Jean-Claude Lissitsky, Jacques Marvaldi and Gilbert Pommier

Unité Interactions entre Systèmes Protéiques et Différenciation dans la Cellule Tumorale, UPRES-A CNRS 6032, Université d’Aix-Marseille I et II, Faculté de Pharmacie, 13385 Marseille; and INSERM U-387 (J.-C.L.), 13009 Marseille, France

Address all correspondence and requests for reprints to: Dr. Jacques Marvaldi, Laboratoire de Biochimie Cellulaire, UPRES-A CNRS 6032, Faculté de Pharmacie, 27 boulevard Jean Moulin, 13385 Marseille Cedex 05, France. E-mail: marvaldi{at}newsup.univ-mrs.fr

To investigate endoproteolytic processing of the type I insulin-like growth factor receptor (IGF-IR), we have examined its structure and activity in the furin-deficient LoVo-C5 cell line. Immunoprecipitation experiments using the monoclonal anti-IGF-IR antibody ({alpha}-IR3) showed that LoVo-C5 cells expressed a major high molecular mass receptor (200 kDa) corresponding to the unprocessed {alpha}/ß pro-receptor. A small amount of successfully cleaved {alpha}/ß heterodimers was also produced, indicating a residual endoproteolytic cleavage activity in these cells. In vitro, a soluble form of recombinant furin was able to cleave the pro-IGF-IR (200 kDa) into {alpha}-subunit (130 kDa) and ß-subunit (97 kDa). Measurement of IGF binding parameters in LoVo-C5 cells indicated a low number of typical type I IGF-binding sites (binding capacity, 5 x 103 sites/cell; Kd, 1.9 nM for IGF-I and 7.0 nM for IGF-II). These findings in LoVo-C5 contrast with those in HT29-D4 cells, which have active furin, and where IGF-IR (2.8 x 104 sites/cell) was fully processed. Moreover, the 200-kDa pro-IGF-IR of LoVo-C5 was unable to induce intracellular signaling, such as ß-subunit tyrosine autophosphorylation and insulin-related substrate-1 tyrosine phosphorylation. Flow immunocytometry analysis using {alpha}-IR3 antibody indicated that LoVo-C5 cells expressed 40% more receptors than HT29-D4 cells, suggesting that in LoVo-C5 cells only the small amount of mature type I IGF-IR binds IGFs with high affinity. To provide evidence for this idea, we showed that mild trypsin treatment of living LoVo-C5 cells partially restored {alpha}/ß cleavage of IGF-IR, and greatly enhanced (6-fold) the IGF-I binding capacity of LoVo-C5 cells, but did not restore IGF-IR signaling activity. Moreover, LoVo-C5 cells were totally unresponsive to IGF-I in terms of cell migration, in contrast to fully processed IGF-IR-HT29-D4 cells. Our data indicate that furin is involved in the endoproteolytic processing of the IGF-IR and suggest that this posttranslational event might be crucial for its ligand binding and signaling activities. However, our data do not exclude that other proprotein convertases could participate to IGF-IR maturation.




This article has been cited by other articles:


Home page
FASEB J.Home page
B. K. McColl, K. Paavonen, T. Karnezis, N. C. Harris, N. Davydova, J. Rothacker, E. C. Nice, K. W. Harder, S. Roufail, M. L. Hibbs, et al.
Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2
FASEB J, April 1, 2007; 21(4): 1088 - 1098.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Endocr. Rev., February 1, 2007; 28(1): 20 - 47.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. E. Bassi, R. Lopez De Cicco, J. Cenna, S. Litwin, E. Cukierman, and A. J.P. Klein-Szanto
PACE4 Expression in Mouse Basal Keratinocytes Results in Basement Membrane Disruption and Acceleration of Tumor Progression
Cancer Res., August 15, 2005; 65(16): 7310 - 7319.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Q. Qiu, A. Basak, M. Mbikay, B. K. Tsang, and A. Gruslin
Role of pro-IGF-II processing by proprotein convertase 4 in human placental development
PNAS, August 2, 2005; 102(31): 11047 - 11052.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Y. Kawashima, S. Kanzaki, F. Yang, T. Kinoshita, K. Hanaki, J.-i. Nagaishi, Y. Ohtsuka, I. Hisatome, H. Ninomoya, E. Nanba, et al.
Mutation at Cleavage Site of Insulin-Like Growth Factor Receptor in a Short-Stature Child Born with Intrauterine Growth Retardation
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4679 - 4687.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. L. de Cicco, J. C. Watson, D. E. Bassi, S. Litwin, and A. J. Klein-Szanto
Simultaneous Expression of Furin and Vascular Endothelial Growth Factor in Human Oral Tongue Squamous Cell Carcinoma Progression
Clin. Cancer Res., July 1, 2004; 10(13): 4480 - 4488.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
P. Duckert, S. Brunak, and N. Blom
Prediction of proprotein convertase cleavage sites
Protein Eng. Des. Sel., January 1, 2004; 17(1): 107 - 112.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. E. Bassi, H. Mahloogi, R. Lopez De Cicco, and A. Klein-Szanto
Increased Furin Activity Enhances the Malignant Phenotype of Human Head and Neck Cancer Cells
Am. J. Pathol., February 1, 2003; 162(2): 439 - 447.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
G. Croissandeau, A. Basak, N. G. Seidah, M. Chretien, and M. Mbikay
Proprotein convertases are important mediators of the adipocyte differentiation of mouse 3T3-L1 cells
J. Cell Sci., March 15, 2002; 115(6): 1203 - 1211.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. E. Bassi, R. L. De Cicco, H. Mahloogi, S. Zucker, G. Thomas, and A. J. P. Klein-Szanto
Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells
PNAS, August 17, 2001; (2001) 191199198.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A.-M. Khatib, G. Siegfried, A. Prat, J. Luis, M. Chretien, P. Metrakos, and N. G. Seidah
Inhibition of Proprotein Convertases Is Associated with Loss of Growth and Tumorigenicity of HT-29 Human Colon Carcinoma Cells. IMPORTANCE OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) RECEPTOR PROCESSING IN IGF-1-MEDIATED FUNCTIONS
J. Biol. Chem., August 10, 2001; 276(33): 30686 - 30693.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. E. Bassi, R. Lopez De Cicco, H. Mahloogi, S. Zucker, G. Thomas, and A. J. P. Klein-Szanto
Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells
PNAS, August 28, 2001; 98(18): 10326 - 10331.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society